January 29 2018 - The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier suffix) and to strengthen the adverse event reporting. This includes making the product's trade name, as well as the non-proprietary name, a mandatory field when reporting an adverse event to the Therapeutic Goods Administration (TGA).
2018-01-01 - The IGBA welcomes the Indian Pharmaceutical Alliance (IPA) to its membership. The IPA represents Indian research-based national pharmaceutical companies. This addition to the IGBA membership is significant in widening the IGBA representation, which now covers this important region.
- Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee
- European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World
- IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to Medicines
- IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly